Maintain EU-CTR compliance: Guidance on the first substantial modification after slim transition and ongoing strategic information management
As the EU-CTR transition period concludes, we now focus on studies that were transitioned with a slim dossier and have pending requirements to fulfill. To ensure ongoing compliance with the regulations, including actions related to the first substantial modification (SM), we invite you to join Parexel’s regulatory expert-led live webinar.
Using practical scenarios to guide the audience, our speakers will discuss the implications of non-compliant dossiers and explore best future practices for managing submission content and prioritization.
What you will learn from the webinar:
- Requirements for studies to comply with EU-CTR, post slim transition
- Recommendations for prioritization and grouping of information within the first SM after transition
- Strategic information management approaches for new and ongoing trials
- Practical advice gained from experience of more than 250 trial transitions
Related Insights
Blog
FDA’s new priority voucher review program: Potential implications and next steps for sponsors
Jun 20, 2025
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023
Related Insights
Blog
FDA’s new priority voucher review program: Potential implications and next steps for sponsors
Jun 20, 2025
Blog
Ensuring future success in a new market by delivering a robust safety database solution
Aug 4, 2023
Video
How to transition existing trials under EU-CTR
Feb 1, 2023
Webinar
How to navigate China’s regulatory environment
Feb 15, 2023
Whitepaper
The Chinese Pharmaceutical Market: Size, R&D, Regulations, Market Access and Innovations
Mar 9, 2023
Playbook
Mitigating risk, protecting potential: Practical strategies that position cell and gene therapy development for success
Mar 28, 2023
Report
New Medicines, Novel Insights: Advancing rare disease drug development
May 22, 2023
Report
New Medicines, Novel Insights: Accelerating development of cell and gene therapies
May 22, 2023
Webinar
Assessing appropriate use of ECAs in clinical trials
May 28, 2023
Blog
Celebrating 40 Years of Rare Disease Progress: WODC Highlights
Jun 6, 2023
Blog
Population variability: important considerations in vaccine development
Jun 14, 2023
Whitepaper
How to prepare for Policy 0070: Challenges and opportunities for clinical data publication in the EU
Jun 28, 2023